Yagi Shusuke, Hirata Yukina, Ise Takayuki, Kusunose Kenya, Yamada Hirotsugu, Fukuda Daiju, Salim Hotimah Masdan, Maimaituxun Gulinu, Nishio Susumu, Takagawa Yuriko, Hama Saori, Matsuura Tomomi, Yamaguchi Koji, Tobiume Takeshi, Soeki Takeshi, Wakatsuki Tetsuzo, Aihara Ken-Ichi, Akaike Masashi, Shimabukuro Michio, Sata Masataka
Department of Cardiovascular Medicine, Tokushima University Graduate School of Biomedical Sciences, 3-18-15, Kuramoto-cho, Tokushima, 770-8503 Japan.
Department of Community Medicine and Human Resource Development, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.
Diabetol Metab Syndr. 2017 Oct 4;9:78. doi: 10.1186/s13098-017-0275-4. eCollection 2017.
It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease.
We administered 100 mg of canagliflozin for 6 months to 13 patients with type 2 diabetes mellitus. We evaluated glycemic control, visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area, and skeletal muscle mass by using impedance methods, and EAT thickness by using echocardiography. Canagliflozin treatment for 6 months decreased hemoglobin A1c level from 7.1 ± 0.5% to 6.7 ± 0.6% (P < 0.05) and decreased EAT thickness from 9.3 ± 2.5 to 7.3 ± 2.0 mm (P < 0.001), along with a trend of decreasing VAT and SAT area. No association was found between any of these changes.
Canagliflozin reduced EAT thickness in patients with type 2 diabetes mellitus independent of its effect on lowering blood glucose, suggesting that canagliflozin may have an effect in preventing cardiovascular events in these patients (UMIN000021327).
选择性钠-葡萄糖协同转运蛋白2抑制剂卡格列净是否能降低心外膜脂肪组织（EAT）厚度尚不清楚，EAT厚度与胰岛素抵抗相关，是冠状动脉疾病的危险因素。
我们对13例2型糖尿病患者给予100mg卡格列净治疗6个月。我们使用阻抗法评估血糖控制、内脏脂肪组织（VAT）面积和皮下脂肪组织（SAT）面积以及骨骼肌质量，并使用超声心动图评估EAT厚度。卡格列净治疗6个月使糖化血红蛋白水平从7.1±0.5%降至6.7±0.6%（P<0.05），EAT厚度从9.3±2.5降至7.3±2.0mm（P<0.001），同时VAT和SAT面积有减小趋势。这些变化之间未发现相关性。
卡格列净可降低2型糖尿病患者的EAT厚度，且独立于其降血糖作用，这表明卡格列净可能对预防这些患者的心血管事件有作用（UMIN000021327）。
